Physician profile
Tapan V Mehta
NPI 1194169755
$99,075.43
in general payments reported to CMS, 2019-2025
16 companies · $68K in 2025
The $68K reported for 2025 was more than what 99% of Vascular Neurology providers received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $321 · 2021: $494 · 2022: $1,429 · 2023: $528 · 2024: $28K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $46K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Travel and Lodging: $17K · Food and Beverage: $4,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $45,850.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,984.00 |
| Travel and Lodging | $16,610.19 |
| Food and Beverage | $4,387.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $29,546.01 | 2025 | Emboguard, Spotlight, Trufill |
| Balt USA, LLC | $27,927.25 | 2021-2025 | Optima Coil System, Revere Hybrid Access Catheter, Carrier Delivery Catheter |
| Medtronic, INC. | $26,052.08 | 2022-2025 | Pipeline, Neuroguard Iep System, Solitaire X |
| Microvention, INC. | $12,241.69 | 2020-2025 | Sofia Ex 5f - 105cm Str, Web Aneurysm Embolization System, Sofia 6f-131cm Str |
| Depuy Synthes Sales INC. | $926.11 | 2023-2025 | Embotrap, Emboguard, N/A |
| Scientia Vascular | $800.00 | 2025 | |
| Imperative Care, INC | $324.24 | 2023-2025 | Zoom 88-T Large Distal Platform |
| Janssen Pharmaceuticals, INC | $221.77 | 2021 | |
| Penumbra, INC. | $199.03 | 2021-2022 | |
| Medtronic USA, INC. | $188.55 | 2020 | |
| Route 92 Medical, INC. | $153.97 | 2025 | |
| Abbott Laboratories | $142.29 | 2022 | |
| Amgen INC. | $134.99 | 2024 | Repatha |
| Silk Road Medical, INC. | $112.48 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Astrazeneca Pharmaceuticals Lp | $104.97 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tapan Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.